首页 > 最新文献

Lancet Respiratory Medicine最新文献

英文 中文
Elucidating the outpatient burden of RSV disease in children 阐明儿童呼吸道合胞病毒病的门诊负担
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-01-09 DOI: 10.1016/s2213-2600(24)00402-8
Fatimah S Dawood, Meredith L McMorrow
No Abstract
没有抽象的
{"title":"Elucidating the outpatient burden of RSV disease in children","authors":"Fatimah S Dawood, Meredith L McMorrow","doi":"10.1016/s2213-2600(24)00402-8","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00402-8","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"24 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142939506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A response to therapy for COPD with dupilumab dupilumab治疗COPD的反应
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-01-03 DOI: 10.1016/s2213-2600(24)00371-0
Surya P Bhatt, Klaus F Rabe, Dave Singh, Mona Bafadhel, Claus F Vogelmeier
No Abstract
没有抽象的
{"title":"A response to therapy for COPD with dupilumab","authors":"Surya P Bhatt, Klaus F Rabe, Dave Singh, Mona Bafadhel, Claus F Vogelmeier","doi":"10.1016/s2213-2600(24)00371-0","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00371-0","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"97 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial Vanzacaftor-tezacaftor-deutivacaftor用于6-11岁囊性纤维化儿童(RIDGELINE试验VX21-121-105):来自单组3期试验的分析
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-01-02 DOI: 10.1016/s2213-2600(24)00407-7
Jordana E Hoppe, Ajay S Kasi, Jessica E Pittman, Renee Jensen, Lena P Thia, Philip Robinson, Pornchai Tirakitsoontorn, Bonnie Ramsey, Marcus A Mall, Jennifer L Taylor-Cousar, Edward F McKone, Elizabeth Tullis, Danieli B Salinas, Jiaqiang Zhu, Yih-Chieh Chen, Violeta Rodriguez-Romero, Patrick R Sosnay, Gwyneth Davies
<h3>Background</h3>In phase 2 trials in people with cystic fibrosis aged 18 years and older, vanzacaftor–tezacaftor–deutivacaftor has been shown to be a safe and effective, once-daily cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Restoring normal CFTR function early in life has the potential to prevent manifestations of cystic fibrosis. We aimed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 6–11 years.<h3>Methods</h3>In this multicentre, single-arm, phase 3 trial (RIDGELINE Trial VX21-121-105), participants were enrolled across 33 clinical sites that care for children with cystic fibrosis in eight countries (Australia, France, Germany, Netherlands, Sweden, Switzerland, the UK, and the USA). Eligible participants were aged 6–11 years with at least one elexacaftor–tezacaftor–ivacaftor-responsive <em>CFTR</em> variant, FEV<sub>1</sub> % predicted of 60% or higher, and stable cystic fibrosis as determined by investigators. Before study treatment, participants were either on stable elexacaftor–tezacaftor–ivacaftor for at least 28 days before screening or received the combination for a 4-week run-in period. Participants then received vanzacaftor–tezacaftor–deutivacaftor (<40 kg bodyweight: vanzacaftor 12 mg, tezacaftor 60 mg, and deutivacaftor 150 mg orally as three fixed-dose combination tablets once daily; ≥40 kg bodyweight: vanzacaftor 20 mg, tezacaftor 100 mg, and deutivacaftor 250 mg orally as two fixed-dose combination tablets once daily (manufactured by Patheon Pharmaceuticals, Cincinnati, OH, USA) from day 1 for 24 weeks. The primary endpoint was safety and tolerability, as measured by adverse events, vital signs, clinical laboratory values, electrocardiograms, and pulse oximetry. Endpoints were analysed in all participants who received at least one dose of vanzacaftor–tezacaftor–deutivacaftor. This trial is registered with <span><span>ClinicalTrials.gov</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span>, <span><span>NCT05422222</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span>, and evaluation of the 6–11-year-old cohort is complete.<h3>Findings</h3>Between Feb 6 and May 18, 2023, 83 children were screened, of whom five were not eligible, and 78 children aged 6-11 years received at least one dose of vanzacaftor–tezacaftor–deutivacaftor. Median age was 9·3 years (IQR 7·6–10·4), 34 (44%) of 78 participants were female, 44 (56%) were male, 71 (91%) were White, one (1%) was Black or African American, and one (1%) was of multiple races. The analysis for these data was completed on Dec 15, 2023. Median expos
在18岁及以上囊性纤维化患者的2期试验中,vanzacaftor-tezacaftor-deutivacaftor已被证明是一种安全有效的、每日一次的囊性纤维化跨膜传导调节剂(CFTR)。在生命早期恢复正常的CFTR功能有可能预防囊性纤维化的表现。我们的目的是评估vanzacaftor-tezacaftor-deutivacaftor在6-11岁囊性纤维化儿童中的安全性、耐受性、有效性和药代动力学。在这项多中心、单臂、3期试验(RIDGELINE试验VX21-121-105)中,参与者来自8个国家(澳大利亚、法国、德国、荷兰、瑞典、瑞士、英国和美国)33个治疗囊性纤维化儿童的临床站点。符合条件的参与者年龄为6-11岁,至少有一种elexacator - tezacator - ivacator -responsive CFTR变体,FEV1预测为60%或更高,并且由研究人员确定为稳定的囊性纤维化。在研究治疗之前,参与者要么在筛选前至少28天使用稳定的elexaftor - tezactor - ivacaftor,要么在4周的磨合期内接受联合治疗。然后,参与者服用vanzacactor - tezacactor - deutivacactor(体重40公斤):vanzacactor 12mg, tezacactor 60mg, deutivacactor 150mg,口服3片固定剂量组合片,每日一次;体重≥40 kg: vanzacaftor 20 mg, tezacaftor 100 mg, deutivacaftor 250 mg,口服2片固定剂量联合片,每日1次(由Patheon Pharmaceuticals, Cincinnati, OH, USA生产),从第1天开始,连续24周。主要终点是安全性和耐受性,通过不良事件、生命体征、临床实验室值、心电图和脉搏血氧测定来衡量。终点分析了所有接受至少一剂vanzacactor - tezacactor - deutivacactor的参与者。该试验已在ClinicalTrials.gov注册,编号NCT05422222, 6 - 11岁队列的评估已经完成。在2023年2月6日至5月18日期间,筛查了83名儿童,其中5名不符合条件,78名6-11岁的儿童接受了至少一剂vanzacaftor-tezacaftor-deutivacaftor。78名参与者中,女性34人(44%),男性44人(56%),白人71人(91%),黑人或非裔美国人1人(1%),多种族1人(1%)。对这些数据的分析于2023年12月15日完成。参与者暴露于vanzacactor - tezacactor - deutivacactor的中位数为168天(IQR 166-170)。78名受试者中有75名(96%)出现不良事件,均为轻度或中度;最常见的事件一般与囊性纤维化表现一致,包括咳嗽(36例[46%])、发热(16例[21%])、头痛(14例[18%])、囊性纤维化感染性肺加重(13例[17%])、口咽部疼痛(13例[17%])。6名(8%)参与者发生了严重的不良事件(2名患有感染性肺恶化,其中1名也未能茁壮成长;1名参与者分别有腺病毒感染、便秘、肺功能测试下降和咳嗽,1名(1%)参与者因咳嗽和疲劳等不良事件被认为可能与研究药物有关而停药。vanzactor - tezactor - deutivactor是安全且耐受性良好的,维持了从elexaftor - tezactor - ivacaftor基线预测的1%的FEV1,并进一步改善了CFTR功能。CFTR功能的改善与基线elexactor - tezactor - ivacaftor值相比,显示了早期恢复正常生理和预防囊性纤维化发生或进展的潜在机会。几乎所有参与者的汗液氯化物都低于囊性纤维化的诊断阈值(60 mmol/L),超过一半的参与者的汗液氯化物水平正常(30 mmol/L)。一项开放标签扩展研究正在收集儿童囊性纤维化的额外长期数据,以证明临床益处和安全性。这些发现将告知卫生保健提供者和囊性纤维化患者早期开始使用CFTR调节剂的益处。FundingVertex药品。
{"title":"Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial","authors":"Jordana E Hoppe, Ajay S Kasi, Jessica E Pittman, Renee Jensen, Lena P Thia, Philip Robinson, Pornchai Tirakitsoontorn, Bonnie Ramsey, Marcus A Mall, Jennifer L Taylor-Cousar, Edward F McKone, Elizabeth Tullis, Danieli B Salinas, Jiaqiang Zhu, Yih-Chieh Chen, Violeta Rodriguez-Romero, Patrick R Sosnay, Gwyneth Davies","doi":"10.1016/s2213-2600(24)00407-7","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00407-7","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;In phase 2 trials in people with cystic fibrosis aged 18 years and older, vanzacaftor–tezacaftor–deutivacaftor has been shown to be a safe and effective, once-daily cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Restoring normal CFTR function early in life has the potential to prevent manifestations of cystic fibrosis. We aimed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 6–11 years.&lt;h3&gt;Methods&lt;/h3&gt;In this multicentre, single-arm, phase 3 trial (RIDGELINE Trial VX21-121-105), participants were enrolled across 33 clinical sites that care for children with cystic fibrosis in eight countries (Australia, France, Germany, Netherlands, Sweden, Switzerland, the UK, and the USA). Eligible participants were aged 6–11 years with at least one elexacaftor–tezacaftor–ivacaftor-responsive &lt;em&gt;CFTR&lt;/em&gt; variant, FEV&lt;sub&gt;1&lt;/sub&gt; % predicted of 60% or higher, and stable cystic fibrosis as determined by investigators. Before study treatment, participants were either on stable elexacaftor–tezacaftor–ivacaftor for at least 28 days before screening or received the combination for a 4-week run-in period. Participants then received vanzacaftor–tezacaftor–deutivacaftor (&lt;40 kg bodyweight: vanzacaftor 12 mg, tezacaftor 60 mg, and deutivacaftor 150 mg orally as three fixed-dose combination tablets once daily; ≥40 kg bodyweight: vanzacaftor 20 mg, tezacaftor 100 mg, and deutivacaftor 250 mg orally as two fixed-dose combination tablets once daily (manufactured by Patheon Pharmaceuticals, Cincinnati, OH, USA) from day 1 for 24 weeks. The primary endpoint was safety and tolerability, as measured by adverse events, vital signs, clinical laboratory values, electrocardiograms, and pulse oximetry. Endpoints were analysed in all participants who received at least one dose of vanzacaftor–tezacaftor–deutivacaftor. This trial is registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, &lt;span&gt;&lt;span&gt;NCT05422222&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, and evaluation of the 6–11-year-old cohort is complete.&lt;h3&gt;Findings&lt;/h3&gt;Between Feb 6 and May 18, 2023, 83 children were screened, of whom five were not eligible, and 78 children aged 6-11 years received at least one dose of vanzacaftor–tezacaftor–deutivacaftor. Median age was 9·3 years (IQR 7·6–10·4), 34 (44%) of 78 participants were female, 44 (56%) were male, 71 (91%) were White, one (1%) was Black or African American, and one (1%) was of multiple races. The analysis for these data was completed on Dec 15, 2023. Median expos","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"34 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142912110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials Vanzacaftor-tezacaftor-deutivacaftor对12岁及以上囊性纤维化患者的疗效(SKYLINE试验VX20-121-102和VX20-121-103):两项随机、主动对照的3期试验结果
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-01-02 DOI: 10.1016/s2213-2600(24)00411-9
Claire Keating, Lael M Yonker, François Vermeulen, Dario Prais, Rachel W Linnemann, Aaron Trimble, Tom Kotsimbos, Joel Mermis, Andrew T Braun, Mark O'Carroll, Sivagurunathan Sutharsan, Bonnie Ramsey, Marcus A Mall, Jennifer L Taylor-Cousar, Edward F McKone, Elizabeth Tullis, Tim Floreth, Peter Michelson, Patrick R Sosnay, Nitin Nair, Alexander Horsley
<h3>Background</h3>The goal of cystic fibrosis transmembrane conductance regulator (CFTR) modulators is to reach normal CFTR function in people with cystic fibrosis. Vanzacaftor–tezacaftor–deutivacaftor restored CFTR function in vitro and in phase 2 trials in participants aged 18 years and older resulting in improvements in CFTR function, as measured by sweat chloride concentrations and lung function as measured by spirometry. We aimed to evaluate the efficacy and safety of vanzacaftor–tezacaftor–deutivacaftor compared with standard of care elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older.<h3>Methods</h3>In two randomised, active-controlled, double-blind, phase 3 trials, individuals aged 12 years and older with stable cystic fibrosis with <em>F508del</em>-minimal function (SKYLINE Trial VX20-121-102) or with <em>F508del-F508del, F508del</em>-residual function, <em>F508del</em>-gating, or elexacaftor–tezacaftor–ivacaftor-responsive-non-<em>F508del</em> genotypes (SKYLINE Trial VX20-121-103) were enrolled at 126 and 159 international sites, respectively. Eligible individuals were entered into a 4-week run-in period, during which they received elexacaftor (200 mg once daily), tezacaftor (100 mg once daily), and ivacaftor (150 mg once every 12 h) as two fixed-dose combination tablets in the morning and one ivacaftor tablet in the evening. They were then randomly assigned (1:1) to either elexacaftor (200 mg once daily), tezacaftor (100 mg once daily), and ivacaftor (150 mg once every 12 h) as two fixed-dose combination tablets in the morning and one ivacaftor tablet in the evening, or vanzacaftor (20 mg once daily), tezacaftor (100 mg once daily), and deutivacaftor (250 mg once daily) as two fixed-dose combination tablets in the morning, for the 52-week treatment period. All participants received matching placebo tablets to maintain the treatment blinding. Randomisation was done using an interactive web-response system and stratified by age, FEV<sub>1</sub> % predicted, sweat chloride concentration, and previous CFTR modulator use, and also by genotype for Trial VX20-121-103. The primary endpoint for both trials was absolute change in FEV<sub>1</sub> % predicted from baseline (most recent value before treatment on day 1) through week 24 (with non-inferiority of vanzacaftor–tezacaftor–deutivacaftor shown if the lower bound of the 95% CI for the primary endpoint was –3·0 or higher). Efficacy was assessed in all participants with the intended <em>CFTR</em> genotype who were randomly assigned to treatment and received at least one dose of study treatment during the treatment period. Safety was assessed in all participants who received at least one dose of study drug during the treatment period. These trials are registered with <span><span>ClinicalTrials.gov</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0
囊性纤维化跨膜传导调节剂(CFTR)的目标是使囊性纤维化患者的CFTR功能达到正常。Vanzacaftor-tezacaftor-deutivacaftor在体外和18岁及以上参与者的2期试验中恢复了CFTR功能,通过汗液氯化物浓度测量CFTR功能,通过肺活量测定法测量肺功能。我们的目的是评估vanzacaftor-tezacaftor-deutivacaftor与标准护理方案eleexaftor - tezacaftor - ivacaftor在12岁及以上囊性纤维化患者中的疗效和安全性。方法在两项随机、主动对照、双盲、3期试验中,分别在126个和159个国际站点招募了年龄在12岁及以上的F508del-minimal功能(SKYLINE试验VX20-121-102)或F508del-F508del、f508del -残差功能、f508del -门控或elexacaftor - tezacaftor - ivacaftor-应答性非f508del基因型(SKYLINE试验VX20-121-103)的稳定囊性纤维化患者。符合条件的个体进入为期4周的磨合期,在此期间,他们在早上接受elexaftor (200mg每日一次),tezacaftor (100mg每日一次)和ivacaftor (150mg每12小时一次)作为两个固定剂量的组合片,在晚上接受一个ivacaftor片。然后,他们被随机分配(1:1),要么是elexacaftor (200 mg每日一次)、tezacaftor (100 mg每日一次)和ivacaftor (150 mg每12小时一次)作为两个固定剂量的联合片,在早上和晚上分别服用一片ivacaftor片,要么是vanzacaftor (20 mg每日一次)、tezacaftor (100 mg每日一次)和deutivacaftor (250 mg每日一次)作为两个固定剂量的联合片,在52周的治疗期间。所有的参与者都接受了匹配的安慰剂片,以维持治疗的盲性。使用交互式网络反应系统进行随机化,并根据年龄、预测FEV1 %、汗液氯化物浓度、以前使用CFTR调节剂以及试验VX20-121-103的基因型进行分层。两项试验的主要终点是从基线(治疗前第1天的最新值)到第24周预测的FEV1 %的绝对变化(如果主要终点的95% CI下限为-3·0或更高,则显示vanzacaftor-tezacaftor-deutivacaftor的非劣效性)。在所有具有预期CFTR基因型的参与者中评估疗效,这些参与者被随机分配到治疗组,并在治疗期间接受至少一剂研究治疗。在治疗期间接受至少一剂研究药物的所有参与者进行了安全性评估。这些试验已在ClinicalTrials.gov注册,编号NCT05033080(试验VX20-121-102)和NCT05076149(试验VX20-121-103),现已完成。在2021年9月14日至2022年10月18日的试验VX20-121-102中,筛选了488名个体,其中435人进入了4周的运行期,随后398人被随机分配并接受至少一剂elexacaftor-tezacaftor-ivacaftor (n=202)或vanzacaftor-tezacaftor-deutivacaftor (n=196)。中位年龄31.0岁(IQR 22.6 ~ 38.5),女性163人(41%),男性235人(59%),白人388人(97%)。在2021年10月27日至2022年10月26日的试验VX20-121-103中,筛选了699名个体,其中597名进入了为期4周的试运行期,随后随机分配573名参与者,接受至少一剂elexacaftor-tezacaftor-ivacaftor (n=289)或vanzacaftor-tezacaftor-deutivacaftor (n=284)。573名参与者中,女性280人(49%),男性293人(51%),白人532人(93%),平均年龄33.1岁(IQR 24.5 ~ 42.2)。试验VX20-121-102从基线到第24周预测的最小二乘平均fev1%的绝对变化,vanzacactor - tezacactor - deutivacactor组为0.5 (SE 0.3)个百分点,而elexacator - tezacactor - ivacaftor组为0.3 (SE 0.3)个百分点(最小二乘平均治疗差异为0.2个百分点[95% CI -0·7至1·1];试验VX20-121-103中,vanzacactor - tezacactor - deutivacactor组与elexacator - tezacactor - ivacaftor组的差异为0.2 (SE为0.3)个百分点(最小二乘平均治疗差为0.2个百分点[95% CI为- 0.05 ~ 0.9];术;0·0001)。大多数不良事件为轻度或中度,最常见的是感染性肺加重(vanzacafor - tezacafor - deutivacaftor联合组480名参与者中有133名[28%],而elexafor - tezacafor - ivacaftor联合组491名参与者中有158名[32%])、咳嗽(108名[23%]对101名[21%])、COVID-19(107名[22%]对127名[26%])和鼻咽炎(102名[21%]对95名[19%])。结论vanzacator - tezacator - deutivacator在预测FEV1 %方面不低于elexafter - tezacator - ivacator,且安全且耐受性良好。 与目前每日两次的标准治疗方案相比,每日一次给药vanzacaftor-tezacaftor-deutivacaftor减轻了治疗负担,有可能提高依从性。CFTR功能的恢复和处理的潜在变异也是应该与当前可用的CFTR调制器进行比较的考虑因素。FundingVertex药品。
{"title":"Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","authors":"Claire Keating, Lael M Yonker, François Vermeulen, Dario Prais, Rachel W Linnemann, Aaron Trimble, Tom Kotsimbos, Joel Mermis, Andrew T Braun, Mark O'Carroll, Sivagurunathan Sutharsan, Bonnie Ramsey, Marcus A Mall, Jennifer L Taylor-Cousar, Edward F McKone, Elizabeth Tullis, Tim Floreth, Peter Michelson, Patrick R Sosnay, Nitin Nair, Alexander Horsley","doi":"10.1016/s2213-2600(24)00411-9","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00411-9","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;The goal of cystic fibrosis transmembrane conductance regulator (CFTR) modulators is to reach normal CFTR function in people with cystic fibrosis. Vanzacaftor–tezacaftor–deutivacaftor restored CFTR function in vitro and in phase 2 trials in participants aged 18 years and older resulting in improvements in CFTR function, as measured by sweat chloride concentrations and lung function as measured by spirometry. We aimed to evaluate the efficacy and safety of vanzacaftor–tezacaftor–deutivacaftor compared with standard of care elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older.&lt;h3&gt;Methods&lt;/h3&gt;In two randomised, active-controlled, double-blind, phase 3 trials, individuals aged 12 years and older with stable cystic fibrosis with &lt;em&gt;F508del&lt;/em&gt;-minimal function (SKYLINE Trial VX20-121-102) or with &lt;em&gt;F508del-F508del, F508del&lt;/em&gt;-residual function, &lt;em&gt;F508del&lt;/em&gt;-gating, or elexacaftor–tezacaftor–ivacaftor-responsive-non-&lt;em&gt;F508del&lt;/em&gt; genotypes (SKYLINE Trial VX20-121-103) were enrolled at 126 and 159 international sites, respectively. Eligible individuals were entered into a 4-week run-in period, during which they received elexacaftor (200 mg once daily), tezacaftor (100 mg once daily), and ivacaftor (150 mg once every 12 h) as two fixed-dose combination tablets in the morning and one ivacaftor tablet in the evening. They were then randomly assigned (1:1) to either elexacaftor (200 mg once daily), tezacaftor (100 mg once daily), and ivacaftor (150 mg once every 12 h) as two fixed-dose combination tablets in the morning and one ivacaftor tablet in the evening, or vanzacaftor (20 mg once daily), tezacaftor (100 mg once daily), and deutivacaftor (250 mg once daily) as two fixed-dose combination tablets in the morning, for the 52-week treatment period. All participants received matching placebo tablets to maintain the treatment blinding. Randomisation was done using an interactive web-response system and stratified by age, FEV&lt;sub&gt;1&lt;/sub&gt; % predicted, sweat chloride concentration, and previous CFTR modulator use, and also by genotype for Trial VX20-121-103. The primary endpoint for both trials was absolute change in FEV&lt;sub&gt;1&lt;/sub&gt; % predicted from baseline (most recent value before treatment on day 1) through week 24 (with non-inferiority of vanzacaftor–tezacaftor–deutivacaftor shown if the lower bound of the 95% CI for the primary endpoint was –3·0 or higher). Efficacy was assessed in all participants with the intended &lt;em&gt;CFTR&lt;/em&gt; genotype who were randomly assigned to treatment and received at least one dose of study treatment during the treatment period. Safety was assessed in all participants who received at least one dose of study drug during the treatment period. These trials are registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"58 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142912109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating uncertainty: asthma biologics during pregnancy. 驾驭不确定性:孕期哮喘生物制剂。
IF 38.7 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-01-01 Epub Date: 2024-08-28 DOI: 10.1016/S2213-2600(24)00248-0
Imran Howell, Aleksandra Howell, Ian Pavord
{"title":"Navigating uncertainty: asthma biologics during pregnancy.","authors":"Imran Howell, Aleksandra Howell, Ian Pavord","doi":"10.1016/S2213-2600(24)00248-0","DOIUrl":"10.1016/S2213-2600(24)00248-0","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":" ","pages":"10-11"},"PeriodicalIF":38.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An international consensus on the use of asthma biologics in pregnancy. 关于妊娠期使用哮喘生物制剂的国际共识。
IF 38.7 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-01-01 Epub Date: 2024-08-28 DOI: 10.1016/S2213-2600(24)00174-7
Jennifer Naftel, David J Jackson, Matthew Coleman, Grainne d'Ancona, Liam G Heaney, Paddy Dennison, Apostolos Bossios, Hitasha Rupani

Uncontrolled asthma is associated with an increased risk of adverse perinatal outcomes. Asthma biologics reduce exacerbation frequency, are steroid sparing, and improve quality of life in people with severe asthma. However, evidence for the use and safety of asthma biologics during pregnancy is scarce, largely because pregnant women were excluded from clinical trials. To help to support clinical teams, we conducted an international modified Delphi study. 141 panellists from 32 countries who were involved in the care of people with severe asthma completed two rounds of online surveys covering key areas surrounding the use of asthma biologics in pregnancy. The results from this international Delphi study emphasise risk versus benefit discussions and shared clinical decision making, with consensus among panellists that asthma biologics can be used during conception and throughout pregnancy, initiated during pregnancy in line with prescribing criteria for non-pregnant people, and initiated or continued during breastfeeding. Collating data through international registries remains essential to inform clinical guidelines.

不受控制的哮喘会增加围产期不良后果的风险。哮喘生物制剂可降低哮喘恶化的频率,减少类固醇用量,改善重症哮喘患者的生活质量。然而,有关妊娠期使用哮喘生物制剂及其安全性的证据却很少,这主要是因为孕妇被排除在临床试验之外。为了帮助支持临床团队,我们开展了一项国际性的改良德尔菲研究。来自 32 个国家的 141 位参与重症哮喘患者治疗的专家完成了两轮在线调查,调查内容涉及妊娠期使用哮喘生物制剂的关键领域。这项国际德尔菲研究的结果强调了风险与收益的讨论和共同临床决策,小组成员一致认为哮喘生物制剂可在受孕期间和整个孕期使用,在孕期开始使用时应符合非孕妇的处方标准,并在母乳喂养期间开始使用或继续使用。通过国际登记处整理数据对于为临床指南提供信息仍然至关重要。
{"title":"An international consensus on the use of asthma biologics in pregnancy.","authors":"Jennifer Naftel, David J Jackson, Matthew Coleman, Grainne d'Ancona, Liam G Heaney, Paddy Dennison, Apostolos Bossios, Hitasha Rupani","doi":"10.1016/S2213-2600(24)00174-7","DOIUrl":"10.1016/S2213-2600(24)00174-7","url":null,"abstract":"<p><p>Uncontrolled asthma is associated with an increased risk of adverse perinatal outcomes. Asthma biologics reduce exacerbation frequency, are steroid sparing, and improve quality of life in people with severe asthma. However, evidence for the use and safety of asthma biologics during pregnancy is scarce, largely because pregnant women were excluded from clinical trials. To help to support clinical teams, we conducted an international modified Delphi study. 141 panellists from 32 countries who were involved in the care of people with severe asthma completed two rounds of online surveys covering key areas surrounding the use of asthma biologics in pregnancy. The results from this international Delphi study emphasise risk versus benefit discussions and shared clinical decision making, with consensus among panellists that asthma biologics can be used during conception and throughout pregnancy, initiated during pregnancy in line with prescribing criteria for non-pregnant people, and initiated or continued during breastfeeding. Collating data through international registries remains essential to inform clinical guidelines.</p>","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":" ","pages":"80-91"},"PeriodicalIF":38.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Collateral caring 抵押品关怀
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-12-19 DOI: 10.1016/s2213-2600(24)00421-1
Hemmings Wu
No Abstract
没有抽象的
{"title":"Collateral caring","authors":"Hemmings Wu","doi":"10.1016/s2213-2600(24)00421-1","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00421-1","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"46 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The UK Tobacco and Vapes Bill: a historic opportunity 英国烟草和电子烟法案:一个历史性的机遇
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-12-18 DOI: 10.1016/s2213-2600(24)00419-3
No Abstract
没有抽象的
{"title":"The UK Tobacco and Vapes Bill: a historic opportunity","authors":"","doi":"10.1016/s2213-2600(24)00419-3","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00419-3","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"146 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142849117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
On the front lines of the sepsis crisis: hurdles faced by sepsis researchers, survivors, and family advocates 在败血症危机的前线:败血症研究人员,幸存者和家庭倡导者面临的障碍
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-12-17 DOI: 10.1016/s2213-2600(24)00420-x
Jackie Duda
No Abstract
无摘要
{"title":"On the front lines of the sepsis crisis: hurdles faced by sepsis researchers, survivors, and family advocates","authors":"Jackie Duda","doi":"10.1016/s2213-2600(24)00420-x","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00420-x","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"42 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142841168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incorrect interpretation of the role of COVID-19 vaccination boosters in saving lives – Authors' reply 对COVID-19疫苗接种助推器在拯救生命中的作用的错误解释——作者的答复
IF 76.2 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2024-12-12 DOI: 10.1016/s2213-2600(24)00363-1
Margaux M I Meslé, Jeremy Brown, Marc-Alain Widdowson, Richard G Pebody
No Abstract
没有抽象的
{"title":"Incorrect interpretation of the role of COVID-19 vaccination boosters in saving lives – Authors' reply","authors":"Margaux M I Meslé, Jeremy Brown, Marc-Alain Widdowson, Richard G Pebody","doi":"10.1016/s2213-2600(24)00363-1","DOIUrl":"https://doi.org/10.1016/s2213-2600(24)00363-1","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"148 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lancet Respiratory Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1